ADMA Stock Analysis: ADMA Biologics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.028m USD | 12M Return: -51% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 29.6M
Qual. Beats: -1
Rev. Trend: 96.9%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ADMA Biologics is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics, primarily targeting immune deficiencies and infectious diseases. It operates through two segments: ADMA BioManufacturing (production) and Plasma Collection Centers (sourcing of source plasma), reflecting a vertically integrated model that controls the supply chain from plasma collection through finished product manufacturing.
The companys marketed products include BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) therapies for primary humoral immunodeficiency (PI), and Nabi-HB, a polyclonal antibody for Hepatitis B post-exposure prophylaxis. ADMA also maintains a development pipeline focused on immunoglobulin-based treatments for S. pneumonia infection, and runs its own source plasma collection facilities to support manufacturing inputs.
Products are sold through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers, both in the United States and internationally. ADMA Biologics was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- IVIG product revenue accelerates on ASCENIV demand
- Plasma center expansion improves vertical integration margins
- Path to sustained profitability drives operating leverage
| Net Income: 165.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -1.53 > 1.0 |
| NWC/Revenue: 85.83% < 20% (prev 64.94%; Δ 20.89% < -1%) |
| CFO/TA 0.19 > 3% & CFO 128.3m > Net Income 165.4m |
| Net Debt (73.8m) to EBITDA (221.5m): 0.33 < 3 |
| Current Ratio: 6.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.0m) vs 12m ago -1.93% < -2% |
| Gross Margin: 61.27% > 18% (prev 52.58%; Δ 8.70% > 0.5%) |
| Asset Turnover: 86.73% > 50% (prev 89.97%; Δ -3.24% > 0%) |
| Interest Coverage Ratio: 29.52 > 6 (EBIT TTM 213.6m / Interest Expense TTM 7.24m) |
| A: 0.66 (Total Current Assets 511.2m - Total Current Liabilities 73.5m) / Total Assets 665.2m |
| B: -0.17 (Retained Earnings -116.3m / Total Assets 665.2m) |
| C: 0.36 (EBIT TTM 213.6m / Avg Total Assets 587.9m) |
| D: 1.42 (Book Value of Equity 390.3m / Total Liabilities 274.9m) |
| Altman-Z'' = 7.68 = AAA |
| DSRI: 1.23 (Receivables 135.9m/99.4m, Revenue 509.9m/459.4m) |
| GMI: 0.86 (GM 52.58% / 61.27%) |
| AQI: 0.68 (AQ_t 0.12 / AQ_t-1 0.18) |
| SGI: 1.11 (Revenue 509.9m / 459.4m) |
| TATA: 0.06 (NI 165.4m - CFO 128.3m) / TA 665.2m) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 04, 2026, the stock is trading at USD 8.95 with a total of 4,366,600 shares traded. Over the past week, the price has changed by +2.64%, over one month by +15.34%, over three months by -3.56% and over the past year by -51.04%.
Current recommended Stop Loss: 8.40 (which is 6.1% or 1.4 ATR below the current price).
ADMA Biologics has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ADMA.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 17.6 | 96.6% |
P/E Trailing = 12.8676
P/E Forward = 10.5042
P/S = 3.9776
P/B = 5.1779
Revenue TTM = 509.9m USD
EBIT TTM = 213.6m USD
EBITDA TTM = 221.5m USD
Long Term Debt = 193.6m USD (from longTermDebt, last quarter)
Short Term Debt = 4.46m USD (from shortTermDebt, last quarter)
Debt = 211.9m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.54m
Net Debt = 73.8m USD (calculated: Debt 211.9m - CCE 138.2m)
Enterprise Value = 2.10b USD (2.03b + Debt 211.9m - CCE 138.2m)
Interest Coverage Ratio = 29.52 (Ebit TTM 213.6m / Interest Expense TTM 7.24m)
EV/FCF = 19.48x (Enterprise Value 2.10b / FCF TTM 107.9m)
FCF Yield = 5.13% (FCF TTM 107.9m / Enterprise Value 2.10b)
FCF Margin = 21.16% (FCF TTM 107.9m / Revenue TTM 509.9m)
Net Margin = 32.43% (Net Income TTM 165.4m / Revenue TTM 509.9m)
Gross Margin = 61.27% ((Revenue TTM 509.9m - Cost of Revenue TTM 197.4m) / Revenue TTM)
Gross Margin QoQ = 70.53% (prev 63.82%)
Tobins Q-Ratio = 3.16 (Enterprise Value 2.10b / Total Assets 665.2m)
Interest Expense / Debt = 3.41% (Interest Expense 7.24m / Debt 211.9m)
Taxrate = 19.86% (41.0m / 206.3m)
NOPAT = 171.2m (EBIT 213.6m * (1 - 19.86%))
Current Ratio = 6.95 (Total Current Assets 511.2m / Total Current Liabilities 73.5m)
Debt / Equity = 0.54 (Debt 211.9m / totalStockholderEquity, last quarter 390.3m)
Debt / EBITDA = 0.33 (Net Debt 73.8m / EBITDA 221.5m)
Debt / FCF = 0.68 (Net Debt 73.8m / FCF TTM 107.9m)
Total Stockholder Equity = 424.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 28.13% (Net Income 165.4m / Total Assets 665.2m)
RoE = 38.97% (Net Income TTM 165.4m / Total Stockholder Equity 424.3m)
RoCE = 34.57% (EBIT 213.6m / Capital Employed (Equity 424.3m + L.T.Debt 193.6m))
RoIC = 29.99% (NOPAT 171.2m / Invested Capital 570.6m)
WACC = 8.60% (E(2.03b)/V(2.24b) * Re(9.21%) + D(211.9m)/V(2.24b) * Rd(3.41%) * (1-Tc(0.20)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 20.0 | Cagr: 2.71%
[DCF] Terminal Value 77.17% ; FCFF base≈101.0m ; Y1≈115.8m ; Y5≈170.4m
[DCF] Fair Price = 10.28 (EV 2.46b - Net Debt 73.8m = Equity 2.38b / Shares 231.8m; r=8.60% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.12 | # QB: -1
Revenue Correlation: 96.93 | Revenue CAGR: 41.86% | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-09-30): EPS=0.21 | Chg30d=-1.57% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=0.81 | Chg30d=-2.01% | Revisions=-20% | GrowthEPS=+23.8% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=1.00 | Chg30d=-5.60% | Revisions=-20% | GrowthEPS=+22.6% | GrowthRev=+31.1%
[Analyst] Revisions Ratio: -20%